4D Molecular raises $90M series B

Gene therapy company 4D Molecular Therapeutics Inc. (Emeryville, Calif.) raised $90 million in an untranched series B round led by new investor Viking Global Investors. Fellow new investors ArrowMark Partners, Janus Henderson Investors, The Biotechnology Value Fund, Mirae Asset Financial Group, Pappas Capital & Chiesi Ventures, Perceptive Advisors, Ridgeback Capital Investments, CureDuchenne Ventures and Berkeley Catalyst Fund also participated, as did existing investor Pfizer Ventures.

4D co-founder and CEO David Kirn told BioCentury the company raised $18.5 million in its series A round. Kirn said the B round will provide the company with enough runway through at least 2H20...